ANTX · AN2 Therapeutics, Inc.

Track ANTX — free

$5.61 -0.10 (-1.75%) At close · Oct 5

Russell 2000 member Rebalance outlook locked

Market Cap

$192.45M

37.74M

Volume · Oct 5 299.96K Avg daily vol (3M) 233.17K

Up next

Latest filing: 10-Q

filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$36.28M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$44.32M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+48.4%

Year over year · more shares

Price change (1Y)

+346.1%

Trailing year

Short interest

6.4%

Latest settlement · 11.8 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Strong Buy Momentum Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.59

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +51%

above

Price vs 50-day avg +3%

above

RSI (14) 61

neutral

MACD trend Positive

52-week position 89%

near high

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Strong

1-month return −4%

trailing

6-month return +90%

trailing

YTD return +401%

this year

Relative strength +78%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $6 › 200d $4 — 50d above 200d

Institutional flow Accumulating

+27% holders QoQ · +28 funds added

Insider flow Distributing

Net -$14.7K over 90 days · 67% sells

Short interest Falling

6.35% of float · ▼ -4.4% MoM · 11.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

66 holders — near 3-yr high, broad support

Squeeze score 88

high risk · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 132%

annualized · 1-yr

Max drawdown −46%

past year

ATR 6.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 2 · 5

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+51% Bullish

Price vs 50-day avg

+3% Bullish

RSI (14)

61 Neutral

MACD trend

Positive Bullish

52-week position

89% Bullish

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $6 › 200d $4 — 50d above 200d

Institutional flow Accumulating

+27% holders QoQ · +28 funds added

Insider flow Distributing

Net -$14.7K over 90 days · 67% sells

Short interest Falling

6.35% of float · ▼ -4.4% MoM · 11.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

66 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $1 Now $6 · 89% Range high $6

vs 200-day avg +51% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
cash, cash equivalents and investments	$79.9M	second quarter of 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ANTX AN2 Therapeutics, Inc. this stock	$192.45M	+400.9%	—	—	6.4%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 65.1%
Net QoQ: +2.7M sh
Top holder: Vivo Capital, LLC

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

2.4M

Days to cover: 11.8d
Change: -110.3K sh

View

Short Volume

Short vol %

58%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

3.0K

Value: $18.0K
As of: Sep 4, 2026

View

Off-Exchange

Off-exchange %

28.4%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$14.7K

Buyers / Sellers: 1 / 2

Buyers Sellers

View

Financials

Net income (FY)

$-35.2M

EPS diluted: $-1.16

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 11, 2026
This year: 14

View

Proposed Sales

Value

$6.1M

Shares: 1.0M
Filed: Aug 17, 2026

View

Exempt Offerings

Offering

$40.0M

Filed: Mar 25, 2026

View

Earnings & Events

Webcasts

Last webcast

Jun 4, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ANTX	+17.0%	-4.0%	+89.7%	+7.3%	+400.9%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	+17.2%	-3.6%	+77.5%	+6.4%	+388.0%

Key facts CIK 1880438 CUSIP 037326105 13F (30d) 6 filings 2 filers Visit website Investor relations

ANTX · AN2 Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance